AstraZeneca, Breast Cancer

AstraZeneca’s Breast Cancer Drug Shows Positive Results In Late-Stage Trial
The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with the standard-of-care treatment, the company said.
AstraZeneca therapy improves breast cancer survival in key trial
Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the disease getting worse in a study, a positive outcome in the development of the therapy key to the company's pipeline.
AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch
The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to grow and a cancer biotech cut staff.
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.
AstraZeneca’s camizestrant shows promise in phase 3 breast cancer study
The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an emergent ESR1 mutation to receive either AZ’s candidate or an aromatase inhibitor (anastrozole or letrozole), both taken alongside a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib).
AstraZeneca's camizestrant shows promise in breast cancer trial
AstraZeneca announced on Wednesday that its drug candidate camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in the first-line treatment of hormone receptor-positive,
AstraZeneca breast cancer drug shows positive results, shares up
Bank of America (NYSE: BAC) analysts estimate a peak sales potential of $6 billion for camizestrant across the SERENA-6 and SERENA-4 trials. They note that SERENA-4 is a first-line (1L) trial requiring success in patients without ESR1 mutations, with data expected in the first half of 2026.
Astrazeneca Stock: Cancer Drug Boosts Market Position
Astrazeneca shares rose nearly 1% following unexpectedly positive interim results from a Phase III trial of its breast cancer drug Camizestrant. The study revealed that patients with hormone receptor-positive,
AstraZeneca therapy improves survival in late-stage breast cancer trial
Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in patients with an advanced form of breast cancer without the disease getting worse in a late-stage clinical trial.
AstraZeneca Breast Cancer Pill Delayed Disease Progression
AstraZeneca Plc’s experimental breast cancer pill helped patients live for longer without their disease worsening, the UK drugmaker said.
FierceBiotech12h
AstraZeneca, eyeing $5B peak sales, reports phase 3 breast cancer win for oral SERD
AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...
AstraZeneca's Investigational Cancer Drug Shows First-Line Benefit In Combination With Widely Cancer Medicines
AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.
AstraZeneca data ‘positive’ for Olema’s palazestrant, says H.C. Wainwright
AstraZeneca (AZN) shared positive interim data from the ongoing SERENA-6 Phase 3 trail evaluating camizestrant and CDK4/6 inhibitors as a ...